Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.35 |
| ▸ | CA2 | P00918 | 8/20 | 0.35 |
| ▸ | CA4 | P22748 | 8/20 | 0.35 |
| ▸ | CA9 | Q16790 | 8/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4788402 | 1.00 | CA1 (0.35) | CA1CA2CA4CA9 | |
| SCHEMBL3494104 | 1.00 | CA1 (0.35) | CA1CA2CA4CA9 | |
| SCHEMBL4289931 | 0.89 | TACR1 (0.31) | — | |
| SCHEMBL3766415 | 0.85 | TACR1 (0.39) | CA1CA2CA4CA9 | |
| SCHEMBL20744897 | 0.85 | TACR1 (0.39) | CA1CA2CA4CA9 | |
| SCHEMBL3766440 | 0.85 | TACR1 (0.39) | CA1CA2CA4CA9 | |
| SCHEMBL23827567 | 0.84 | PDK1 (0.33) | CA1CA2CA4CA9 | |
| SCHEMBL23827565 | 0.84 | PDK1 (0.33) | CA1CA2CA4CA9 | |
| SCHEMBL4281522 | 0.84 | KDM4E (0.35) | — | |
| SCHEMBL29942784 | 0.81 | FNTA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| CN-106488910-B | Inhibitors of KRAS G12C | 亚瑞克西斯制药公司 | 2020-07-31 | — | — | CN | disclosed |
| EP-3636639-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| EP-3055290-B1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10111874-B2 | Combination therapies for treatment of cancer | ARAXES PHARMA LLC (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| EP-3193851-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| WO-2016044772-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CA1 2639/4885CA2 1729/4885CA4 3352/4885 |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | CA1 1236/4885CA2 1129/4885CA4 1582/4885 |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | CA1 2921/4885CA2 1657/4885CA4 2966/4885 |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CA1 2921/4885CA2 1657/4885CA4 2966/4885 |
| US-10111874-B2 | Combination therapies for treatment of cancer | KRAS, TP53, HRAS | CA1 3457/4885CA2 2496/4885CA4 701/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CA1 2921/4885CA2 1657/4885CA4 2966/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CA1 2639/4885CA2 1729/4885CA4 3352/4885 |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | CA1 2935/4885CA2 1800/4885CA4 3339/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CA1 2639/4885CA2 1729/4885CA4 3352/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CA1 2639/4885CA2 1729/4885CA4 3352/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CA1 2639/4885CA2 1729/4885CA4 3352/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | CA1 3457/4885CA2 2496/4885CA4 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.